WaveMan
WaveMan · Company
LITS · Lite Strategy, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

LITS Lite Strategy (LITS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001262104
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
9
13F, latest reported quarter

What the filings say about LITS

Insiders, 180 days
+$21.5K net bought
1 buyer

Lite Strategy insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Lite Strategy, Inc. insiders bought a net $21.5K of stock across 6 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Flynn James P
Director
BUY
2026-06-25 SECtraded 2026-06-24
25,000
$21.5K
+24.4%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Dec 19, 2025.
  • -28.2% median (-28.2% mean) 90-day return after 2 previous buys.
  • The trade is 20.0% of the 125,000 shares held after it.
  • No other insider bought within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Flynn James P bought about $21.5K of LITS on Jun 24, 2026; 9 funds added in the latest 13F quarter.
Flynn James P
Director
BUY
2025-12-22 SECtraded 2025-12-19
70,000
$98.0K
-18.2%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 19, 2025.
  • The trade is 70.0% of the 100,000 shares held after it.
  • No other insider bought within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Flynn James P bought about $98.0K of LITS on Dec 19, 2025, the largest insider purchase at the company on our record; 9 funds added in the latest 13F quarter.
Schornstein Alexander
SELL
2025-12-22 SECtraded 2025-12-18
690,611
$946.1K
-18.2%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 18.8% of the 3,674,862 shares held after it.
  • No other insider sold within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Schornstein Alexander sold about $946.1K of LITS on Dec 18, 2025, the largest insider sale at the company on our record; 9 funds added in the latest 13F quarter.
Flynn James P
Director
BUY
2025-11-20 SECtraded 2025-11-19
12,100
$22.7K
-34.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 40.3% of the 30,000 shares held after it.
  • No other insider bought within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Flynn James P bought about $22.7K of LITS on Nov 19, 2025, the largest insider purchase at the company on our record; 9 funds added in the latest 13F quarter.
Glover Nicholas
Director
BUY
2026-10-26 SECtraded 2025-07-23
1,000
$6.0K
n/a
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jul 22, 2025.
  • The trade is 50.0% of the 2,000 shares held after it.
  • No other insider bought within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Glover Nicholas bought about $6.0K of LITS on Jul 23, 2025; 9 funds added in the latest 13F quarter.
6 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 1 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$21.5K over 180 days
more than 69% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
9 funds bought in last quarter
below 86% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
$4.9M repurchased, FY to 2026-06-30
below 80% of Pharma & Biotech
Short interest
0.7% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 78% of Pharma & Biotech
What changed in the last 30 days
Oct 26Director Glover Nicholas bought $12.6K (2 trades, Jul 22, 2025 to Jul 23, 2025)

Watch LITS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-40.1%12M
-60%-33%-6%+21%2025-102025-122026-022026-042026-062026-082026-10 2025-12-18 · Schornstein Alexander sold $946.1K2025-12-19 · Flynn James P bought $98.0K2025-11-19 · Flynn James P bought $22.7K2026-06-24 · Flynn James P bought $21.5K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns LITS: institutional holders (13F)

13F holdings, latest reported quarter
RENAISSANCE TECHNOLOGIES LLC
1,247,350 sh
$1.2M
VANGUARD CAPITAL MANAGEMENT LLC
1,021,892 sh
$942.2K
RLH Capital LLC
806,433 sh
$743.9K
TWO SIGMA INVESTMENTS, LP
557,011 sh
$513.8K
GEODE CAPITAL MANAGEMENT, LLC
365,019 sh
$337.1K

Congress trades in LITS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

LITS planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

LITS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$102.0K position · as of 2026-06-30
0.0%
Nomura Healthcare Fund
$27.7K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$6.8K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$206.8K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$333.9K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$15.9K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2021
$2.5M
$268.6K
$1.3M
-79%
-27%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $21.5K bought by insiders over 180 days, 9 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

LITS financials

Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2024-07-01 to 2025-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-243.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-233.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-227.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2026-062025-062024-062023-12
Revenuen/a$0$65.3Mn/a
Operating income-$66.6M-$17.5M$14.5Mn/a
Net income-$71.2M-$15.9M$18.0Mn/a
EPS (diluted)-2.06-2.392.67n/a
Operating cash flow-$9.1M-$20.8M-$50.5Mn/a
Cash$5.7M$18.0M$3.7Mn/a
Buybacks$4.9M$0n/an/a
Dividends paidn/a$0$11.7M$11.7M
SEC XBRL, fiscal years, as known on 2026-10-28

LITS Stock Sonar score 5/7 axes

Find similar shapesCompare

LITS ranks highest on insider conviction (62nd percentile) and risk and compliance (54th), and lowest on profitability (10th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
10
Inputs
  • Return on equity-243.0% · 14 pct, sector of 545
  • Return on assets-233.4% · 9 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-227.4% · 8 pct, sector of 576
Growth
50
Inputs
  • Revenue growth, YoY-100.0% · 0 pct, sector of 505
  • Backlog growth, YoY+1596% · 100 pct, sector of 40
Insider conviction
62
Inputs
  • Net Form 4 buying (codes P and S), 180d$22K · 68 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
14
Inputs
  • Funds adding, latest quarter9 · 14 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
54
Inputs
  • Short interest, % of float+0.7% · 84 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+17.8% · 23 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

LITS filings, in plain words

Are Lite Strategy insiders buying or selling LITS?

In the 180 days to 2026-10-28, Lite Strategy insiders were net buyers, a net $21.5K across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-28, Lite Strategy insiders were net buyers of LITS, a net $21.5K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies